James Wilson
Family Medicine · West Brookfield, MANPI 1285622365
Payments from drug & device makers
Across 224 payments — averaging $17.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lundbeck LLC$1K
- AbbVie$799
- Lilly USA, LLC$261
- AstraZeneca$242
- Vanda Pharmaceuticals Inc.$207
- Corium, LLC$200
- plus $1K from 26 others
What the payments were for
- Food & beverage$3,90997%
- Education$1073%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lundbeck LLC | 49 | $1,081 |
| AbbVie | 44 | $799 |
| Lilly USA, LLC | 11 | $261 |
| AstraZeneca | 12 | $242 |
| Vanda Pharmaceuticals Inc. | 20 | $207 |
| Corium, LLC | 25 | $200 |
| Abbott | 11 | $187 |
| Phathom Pharmaceuticals, Inc. | 8 | $127 |
| Indivior Inc. | 4 | $125 |
| Gilead | 5 | $88 |
| Novo Nordisk | 4 | $84 |
| Paratek Pharmaceuticals, Inc. | 4 | $79 |
| Johnson & Johnson | 3 | $74 |
| Neurocrine Biosciences, Inc. | 3 | $60 |
| Ardelyx, Inc. | 3 | $50 |
| Exact Sciences | 2 | $35 |
| Inogen, Inc. | 1 | $33 |
| Corcept Therapeutics | 1 | $27 |
| Scpharmaceuticals Inc. | 1 | $27 |
| Verona Pharma, Inc. | 1 | $25 |
| Braeburn Inc. | 1 | $24 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $24 |
| Pfizer | 1 | $23 |
| Teva Pharmaceuticals USA, Inc. | 1 | $17 |
| Viatris Specialty LLC | 1 | $17 |
| Novartis | 1 | $16 |
| Amgen | 1 | $16 |
| Valinor Pharma, LLC | 1 | $15 |
| Acella Pharmaceuticals, LLC | 1 | $14 |
| Axsome Therapeutics, Inc. | 1 | $14 |
| Alkermes, Inc. | 1 | $14 |
| Kowa Pharmaceuticals America, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- KISUNLA$114
How this compares
$4,016 in reported general payments places this provider in the 90th percentile of 1,049 family medicine providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TrulicityDulaglutide | 260 | $278,078 |
| EliquisApixaban | 169 | $156,699 |
| OzempicSemaglutide | 115 | $138,228 |
| JardianceEmpagliflozin | 102 | $99,565 |
| RexultiBrexpiprazole | 46 | $76,174 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 100 | $71,926 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 373 | $45,389 |
| SuboxoneBuprenorphine Hcl/Naloxone Hcl | 62 | $39,141 |
| FarxigaDapagliflozin Propanediol | 47 | $37,827 |
| XareltoRivaroxaban | 41 | $32,047 |
| MounjaroTirzepatide | 30 | $31,389 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 31 | $20,495 |
| JanuviaSitagliptin Phosphate | 18 | $15,143 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 30 | $12,194 |
| Breo ElliptaFluticasone/Vilanterol | 26 | $10,988 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity, Mounjaro | $261 | $309,467290 claims |
| PfizerEliquis | $23 | $156,699169 claims |
| Novo NordiskOzempic | $84 | $138,228115 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $242 | $48,20963 claims |
| Indivior Inc.Suboxone | $125 | $39,14162 claims |
| Johnson & JohnsonXarelto | $74 | $32,04741 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,049 family medicine providers in Massachusetts.
Other family medicine in West Brookfield
- Robert BeckWestford$2.1M
- Katherine Gergen BarnettBoston$226K
- Peter O'DwyerBoston$163K
- Kelly LannuttiWeymouth$122K
- Larry CulpepperBoston$109K
- Jennifer WeylerWorcester$105K
- Megan McCoyFramingham$75K
- Kristina GraceyWorcester$73K
- Suzanne MitchellBoston$69K
- John GrievesonLowell$24K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.